دورية أكاديمية
Medroxyprogesterone acetate in the management of cancer cachexia.
| العنوان: | Medroxyprogesterone acetate in the management of cancer cachexia. |
|---|---|
| المؤلفون: | Madeddu C; Department of Medical Oncology, University of Cagliari, SS 554, km 4.500, 09042 Monserrato (Cagliari), Italy. mantovan@medicina.unica.it, Macciò A, Panzone F, Tanca FM, Mantovani G |
| المصدر: | Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2009 Jun; Vol. 10 (8), pp. 1359-66. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 100897346 Publication Model: Print Cited Medium: Internet ISSN: 1744-7666 (Electronic) Linking ISSN: 14656566 NLM ISO Abbreviation: Expert Opin Pharmacother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: London : Ashley Publications, c1999- |
| مواضيع طبية MeSH: | Cachexia/*drug therapy , Medroxyprogesterone Acetate/*therapeutic use , Neoplasms/*complications, Animals ; Cachexia/etiology ; Humans |
| مستخلص: | Background: Medroxyprogesterone acetate (MPA) is a synthetic, orally active derivative of the natural steroid hormone progesterone, widely used in oncology both in the endocrine treatment of hormone-related cancers and as supportive therapy in the cachexia syndrome. Objective: The anticachectic mechanisms of medroxyprogesterone, beyond its endocrine activity, are described to explain its therapeutic efficacy in the treatment of cachexia. Methods: After reviewing its pathophysiology and preclinical studies, the main clinical trials on the use of medroxyprogesterone acetate in cancer cachexia, are reviewed. Results/conclusions: Progestagens, including MPA, are at present the only approved drugs in Europe for the clinical treatment of cancer-related anorexia/cachexia syndrome. Placebo-controlled trials on the effect of MPA on cachexia have generally reported an improvement of both anorexia and body weight as well as of quality-of-life parameters. However, the weight gain was due to increased body fat, while fat-free mass was not significantly influenced by MPA treatment. Moreover, very recently the combination of MPA with other new anticachectic agents has been suggested as a way of ameliorating their efficacy in the treatment of cachexia. |
| Number of References: | 48 |
| المشرفين على المادة: | C2QI4IOI2G (Medroxyprogesterone Acetate) |
| تواريخ الأحداث: | Date Created: 20090519 Date Completed: 20090813 Latest Revision: 20131121 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1517/14656560902960162 |
| PMID: | 19445562 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7666 |
|---|---|
| DOI: | 10.1517/14656560902960162 |